Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514552 | 0.92 | RIPK1 (0.48) | PRMT5WDR77RIPK1ALDH1A1GPR119 | |
| SCHEMBL24365782 | 0.86 | RIPK1 (0.63) | PRMT5WDR77RIPK1ALDH1A1LMNA | |
| SCHEMBL17114341 | 0.86 | RIPK1 (0.63) | PRMT5WDR77RIPK1ALDH1A1LMNA | |
| SCHEMBL7469150 | 0.86 | RIPK1 (0.63) | PRMT5WDR77RIPK1ALDH1A1LMNA | |
| SCHEMBL28670876 | 0.86 | LMNA (0.44) | PRMT5WDR77RIPK1ALDH1A1LMNA | |
| SCHEMBL22473247 | 0.86 | LMNA (0.44) | PRMT5WDR77RIPK1ALDH1A1LMNA | |
| Water SCHEMBL28772891 | 0.85 | RIPK1 (0.46) | RIPK1ALDH1A1LMNANPC1TSHR | |
| SCHEMBL29585212 | 0.85 | HSD17B10 (0.55) | RIPK1ALDH1A1LMNAGPR119HSD17B10 | |
| SCHEMBL21611486 | 0.85 | RIPK1 (0.48) | RIPK1ALDH1A1LMNAHSD11B1NPC1 | |
| SCHEMBL23646472 | 0.85 | RIPK1 (0.48) | RIPK1ALDH1A1LMNAHSD11B1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222298-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | Janssen Pharmaceutica N.V. (BE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009058801-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| EP-1565467-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Proskelia SAS (FR) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |